-
Mashup Score: 15Tandem Thursday Breakfast Symposium: The Evolving Paradigm of Sickle Cell Disease Management - 3 month(s) ago
The paradigm of sickle cell disease management is rapidly evolving with exciting new advances in transplant and genetic therapies. Are you ready for these changes? This breakfast symposium will provide detailed information to enable you to effectively counsel patients affected by sickle cell disease. Donβt miss this insightful and interactive symposium featuring some of the leading voices in sickle cell disease research and care. This activity is supported by an independent medical education grant from Vertex Pharmaceuticals.
Source: tandem.confex.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 146
The FDA approved the first cell-based gene therapies, Casgevy and Lyfgenia, for the treatment of sickle cell disease in patients 12 years and older.
Source: www.fda.govCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 146
The FDA approved the first cell-based gene therapies, Casgevy and Lyfgenia, for the treatment of sickle cell disease in patients 12 years and older.
Source: www.fda.govCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 146
The FDA approved the first cell-based gene therapies, Casgevy and Lyfgenia, for the treatment of sickle cell disease in patients 12 years and older.
Source: www.fda.govCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 146
The FDA approved the first cell-based gene therapies, Casgevy and Lyfgenia, for the treatment of sickle cell disease in patients 12 years and older.
Source: www.fda.govCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 143
The FDA approved the first cell-based gene therapies, Casgevy and Lyfgenia, for the treatment of sickle cell disease in patients 12 years and older.
Source: www.fda.govCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 143
The FDA approved the first cell-based gene therapies, Casgevy and Lyfgenia, for the treatment of sickle cell disease in patients 12 years and older.
Source: www.fda.govCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 143
The FDA approved the first cell-based gene therapies, Casgevy and Lyfgenia, for the treatment of sickle cell disease in patients 12 years and older.
Source: www.fda.govCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 143
The FDA approved the first cell-based gene therapies, Casgevy and Lyfgenia, for the treatment of sickle cell disease in patients 12 years and older.
Source: www.fda.govCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 143
The FDA approved the first cell-based gene therapies, Casgevy and Lyfgenia, for the treatment of sickle cell disease in patients 12 years and older.
Source: www.fda.govCategories: General Medicine News, Hem/OncsTweet
Join me for a CME breakfast on Thursday in Stars at Night Ballroom B2 & B3 at the #Tandem24 meeting: The Evolving Paradigm of Sickle Cell Disease Management. See more details at https://t.co/9HmB3TK47Z https://t.co/nr6xsrPnct